In the current study, we demonstrated that miR-206 could suppress EMT process and cisplatin resistance of lung adenocarcinoma cells, partly through targeting MET and its downstream PI3K/AKT/ mTOR pathway both in vitro and in vivo. This evidence concerns the gene MTOR and lung adenocarcinoma.